A Comprehensive Review on Analytical Method Development and Validation for SGLT-2 Inhibitors by HPLC in Its API and Dosage Form

Manojkumar K. Munde; Nilesh S. Kulkarni; Nikita B. Rukhe; Dhanya B. Sen

doi:10.5958/0974-360X.2020.00616.2

Research Journal of Pharmacy and Technology

ISSN

0974-360X (Online)
0974-3618 (Print)

Submit Article

A Comprehensive Review on Analytical Method Development and Validation for SGLT-2 Inhibitors by HPLC in Its API and Dosage Form

Author(s): Manojkumar K. Munde, Nilesh S. Kulkarni, Nikita B. Rukhe, Dhanya B. Sen

Email(s): manojpcist@gmail.com

DOI: 10.5958/0974-360X.2020.00616.2

Address: Manojkumar K. Munde1,2*, Nilesh S. Kulkarni2, Nikita B. Rukhe2, Dhanya B. Sen1
1Department of Pharmacy, Sumandeep Vidyapeeth Deemed to be University, Piparia, Vadodara-391760, Gujarat, India.
2PES Modern College of Pharmacy (for Ladies), Moshi, Pune-412105, Maharashtra, India. Affiliated to Savitribai Phule Pune University, Pune.
*Corresponding Author

Published In: Volume - 13, Issue - 7, Year - 2020

View HTML

View PDF

ABSTRACT:
SGLT-2 is the newly developed class of antidiabetic medicine also called as gliflozins. Empagliflozin, dapagliflozin and canagliflozin are the SGLT-2 class inhibitors for the treatment of type II diabetes mellitus. SGLT-2 inhibitors shows the 82% of plasma protein binding, 36.8% of partitioning of red blood cells, 78% of bioavailability, 5.6 to 13.1 hrs half life in oral route of administration. In this review we complied analytical methods for the development and determination of the SGLT-2 inhibitors. Table no. 1, 2, 3 shows the analytical method development and validation of empagliflozin dapagliflozin and canagliflozin alone and with its combination by the HPLC method respectively also table no. 4 shows the various formulations available in SGLT-2 Inhibitors.

Keywords:

Cite this article:
Manojkumar K. Munde, Nilesh S. Kulkarni, Nikita B. Rukhe, Dhanya B. Sen. A Comprehensive Review on Analytical Method Development and Validation for SGLT-2 Inhibitors by HPLC in Its API and Dosage Form. Research J. Pharm. and Tech 2020; 13(7): 3472-3479. doi: 10.5958/0974-360X.2020.00616.2

Cite(Electronic):
Manojkumar K. Munde, Nilesh S. Kulkarni, Nikita B. Rukhe, Dhanya B. Sen. A Comprehensive Review on Analytical Method Development and Validation for SGLT-2 Inhibitors by HPLC in Its API and Dosage Form. Research J. Pharm. and Tech 2020; 13(7): 3472-3479. doi: 10.5958/0974-360X.2020.00616.2 Available on: https://rjptonline.org/AbstractView.aspx?PID=2020-13-7-76

REFERENCES:

1. https://en.wikipedia.org/wiki/SGLT2_inhibitor.

2. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4269649.

3. https://www.google.com/searchq=mechanism+of+action+of+sglt2+inhibitorsandrlz=1C1ASVA_enIN785 IN785 and source=lnms and tbm=isch and sa=Xandved=0ahUKEwi66pbt IPjAhW1mOYKHbKSDK4Q_AUIECgBandbiw=1366andbih=625#imgrc=qHcGnfD7qk71XM.

4. https://medlineplus.gov/druginfo/meds/a614043.html.

5. https://pubchem.ncbi.nlm.nih.gov/compound/empagliflozin.

6. Kimura G. Diuretic action of sodium-glucose co transporter 2 inhibitors and its importance in the management of heart failure. Circ J 2016 25; 80(11): 2277-81.

7. Vallon V, Thomson SC. Targeting renal glucose reabsorption to treat hyperglycaemia. The pleiotropic effects of SGLT2 inhibition.Diabetologia. 2017;60(2): 215-25.

8. Chawla G, Chaudhary KK. A complete review of empagliflozin: Most specific and potent SGLT2 inhibitor used for the treatment of type 2 diabetes mellitus Diabetes and Metabolic Syndrome. Clin Res and Rev 2019;13:2001-08.

9. Heise T, Seman L, Macha S, Jones P, Marquart A, Pinnetti S. Safety, tolerability, pharmacokinetics and pharmacodynamics of multiple rising doses of empagliflozin in patients with type 2 diabetes mellitus. Diabetes Ther. 2013;4(2):331-45.

10. Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Køber LV. et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373(23):2247-57.

11. Christoph W, John ML, Silvio EI, David F, Michaela M. Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease. Circulation. 2018;137:119-29.

12. Seman L, Macha S, Nehmiz G, Simons G, Ren B, Pinnetti S. Empagliflozin, a potent and selective SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin. Pharmacol Drug Dev. 2013;2(2):152-61.

13. http://www.rxlist.com/glyxambi-drug/clinical-pharmacology.htm.

14. Taub ME, Ludwig-Schwellinger E, Ishiguro N, Kishimoto W, Yu H, Wagner K. Sex species and tissue-specific metabolism of empagliflozin in male mouse kidney forms an unstable hemiacetal metabolite that degrades to 4-Hydroxycrotonaldehyde, a reactive and cytotoxic species. Chem Res Toxicol. 2015;28(1):103-15.

15. Scheen AJ. Pharmacodynamics, efficacy and safety of sodiumeglucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs. 2015;75(1):33-59.

16. Scheen AJ. Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor. Clin Pharmaco 2014;53(3):213-25.

17. Tomlinson B, Hu M, Zhang Y, Chan P, Liu ZM. Evaluation of the pharmacokinetics, pharmacodynamics and clinical efficacy of empagliflozin for the treatment of type 2 diabetes. Expert Opin Drug Metabol Toxicol 2016 ;21:1-3.

18. https://medlineplus.gov/druginfo/meds/a614043.html.

19. Padmaja N, Veerabhadram G. Method development and validation of Rp-Hplc method for the estimation of empagliflozin in API. Int J Pharm Sci Res. 2016; 7(2): 724-27.

20. Soumika M, Sangeetha E, Mahender L .Method development and validation of empagliflozin by Rp-Hplc in bulk and pharmaceutical dosage Form . Int J Adv Pharma Sci 2016; 7(1): 3040-42.

21. Bolle SK, Illendula S, Rao KNV, Dutt HR. A new simple method development, validation and forced degradation studies of empagliflozin by using Rp-Hplc. Int J Pharm Bio Sci 2019; 9(1): 25-35.

22. Nakka M, Nakka S, Utpala BN. A validated isocratic chiral liquid chromatographic method for the enantio selective separation of empagliflozin on new immobilized amylose based stationary phase. Int J Inov Pharma Sci Res. 2017;10(5):81-92.

23. Shyamala, M.Soumika, E.Sangeetha, L.Mahender. Method development and validation of empagliflozin by Rp-Hplc In bulk and pharmaceutical dosage form. Int J Adv Pharm Sci 2016;7(1): 3040-42.

24. Geetha SA, Rajitha G, Yadav RY, Uma P. Analytical method development and validation of new stability-indicating reverse-phase high-performance liquid chromatography method for simultaneous estimation of metformin hydrochloride and empagliflozin in tablet dosage form. Asian J Pharm Clin Res 2019 ;12(1): 241-44.

25. C. Rupasi , M. Bhagavan. Development and validation of stability indicating Rp-Hplc method for the simultaneous estimation of metformin hydrochloride and empagliflozin in bulk and in a synthetic mixture. Int J Pharm 2016; 6(4): 138-47.

26. Patel AM, Chaudhary AB. Stability indicating Rp-Hplc method development and validation for estimation of empagliflozin and metformin Hcl. World J Pharm Sci 6(9): 872-85.

27. Bakshi A, Mounika A, Bhutada S, Dr. M. Bhagvan. Simultaneous estimation of empagliflozin and linagliptin by RP-HPLC method. World J Pharm Sci 7(8) :1062-71.

28. Nagunath S, Subramanian NS, Reddy K. Stability indicating method development and validation for simultaneous estimation of linagliptin and empagliflozin in tablets by HPLC. Saudi J Med Pharm Sci 2018;4(8) : 884-96.

29. Ghadir AK, Ismail S, Mohammed SG, Mohammed AH. Validated RP-HPLC method for simultaneous determination of canagliflozin, dapagliflozin, empagliflozin and metformin, IJPCBS 2018; 8(1): 1-13.

30. Bassam M, Ayoub SM. LC–MS/MS determination of empagliflozin and metformin. J Chroma Sci 2017;55 (7):742–47.

31. Vinay KD, Rao NS. A new validated stability indicating Rp-Hplc method for simutaneous estimation of metformin hydrochloride and empagliflozin in tablet dosage forms. Int Res J Pharm Med Sci. 2018;1(5):16-22.

32. Madhusudhan P , Reddy MR , Devanna N. RPHPLC method development and validation for simultaneous determination of linagliptin and empagliflozine in tablet dosage form. Int Adv Res J Sci, Eng andTech. 2015;2(2) :95-99.

33. Rao MS, Anusha K, Syed M. stability indicating Rp-Hplc method for simultaneous estimation of empagliflozin and linagliptin in bulk and pharmaceutical dosage forms. J Syn Natu Chem 2017;2(1):1-6.

34. http://ajrconline.org/abstractview.aspx?PID=2017-10-6-11.

35. Naazneen S, Sridevi A . Development and validation of stability indicating RP-HPLC method for simultaneous estimation of empagliflozine and linagliptin in tablet formulation. Scholars Research Library Der Pharm Let 2016;8(17):57-65.

36. Suma BV ,Deveswaran R. An overview on analytical methods for dapagliflozin- an antidiabetic drug.Int J Pharm Sci Res. 2019;10(6): 2688-92.

37. https://www.google.com/search?q=dapagliflozinandrlz=1C1ASVA_enIN785IN785andoq=dapaandaqs=chrome.1.69i57j0l5.5290j0j8andsourceid=chromeandie=UTF-8.

38. Debata J, Kumar S, Jha SK, Khan A. A new Rp-Hplc method development and validation of dapagliflozin in bulk and tablet dosage form. Int J Drug Dev Res. 2017;9(2):48-51.

39. Sanagapati M, Dhanalakshmi K ,Reddy N, Sreenivasa S. Method development and validation of dapagliflozin in API by Rp-Hplc and UV-spectroscopy. Int J Pharm Sci Drug Res. 2014; 6(3): 250-52.

40. Mante GV, Hemke AT, Umekar MJ. RP-HPLC method for estimation of dapagliflozin from its tablet. Int J Chem Tech Res. 2018;11(01): 242-48.

41. Shakirbash S. Development and validation of dapagliflozin by reversed-phase high-performance liquid chromatography method and it forced degradation studies. Asian J Pharm Clin Res. 2017;10(11):101-05.

42. Sanagapati M, Dhanalakshmi K, Reddy N, Sreenivasa S. Development and validation of a RP-HPLC method for the estimation of dapagliflozin in API. Int J Pharm sci res 2014;5(12): 5394-97.

43. Jeyabaskaran M, Rambabu C, Lakshmi MS. Stability indicating Rp-Hplc method for estimation of dapagliflozin in bulk and tablet dosage form. ICJPIR 2015;2(4):69-78.

44. Padmaja BR, Sivagami B, Chandrasekar R, Babu MN. A highly validated Rp-Hplc method development for the simultaneous estimation of dapagliflozin and saxagliptin in tablet dosage forms. Int J Pharma Sci Drug Res 2018;10(5):372-78.

45. Ghadir AK, Ismail S, Mohammed SG, Mohammed AH. Validated Rp-Hplc method for simultaneous determination of canagliflozin, dapagliflozin, empagliflozin and metformin. Int J Pharma chem bio sci. 2018;8(1):1-13.

46. Kommineni V, Chowdary KPR, Prasad SV. Development of a new stability indicating RP-HPLC method for simultaneous estimation of saxagliptine and dapagliflozin and its validation as per Ich guidelines. Indo American J Pharma Sci. 2017;4(09):2920-32.

47. Mohammad Y, Gowri SD . A validated stability indicating high-performance liquid chromatographic method for simultaneous determination of metformin hcl and dapagliflozin in bulk drug and tablet dosage form. Asian J Pharm Clin Res 2015;8(3):320-26.

48. Singh N, Bansal P, Maithani M, Chauhan Y. Development and validation of stability-indicating RP-HPLC method for simultaneous determination of dapagliflozin and saxagliptin in fixed-dose combination. New J Chem:1-28.

49. Sanagapati M, Dhanalakshmi K, Nagarjuna RG, Sreenivasa S. Method development and validation of dapagliflozin in API by Rp-Hplc and UV-Spectroscopy. Int J Pharma Sci Drug Res 2014; 6(3):250-52.

50. Housheh S, Bachour V. Analysis of canagliflozin, review. World J Pharm Res;6(4):306-16.

51. https://www.google.com/search?q=canagliflozinandrlz=1C1ASVA_enIN785IN785andoq=canagandaqs=chrome.1.69i57j0l5.9410j0j7andsourceid =chromeandie=UTF-8.

52. Marella VL, Syed A, Prasanna L, Nalluri BN. A novel validated RP-HPLC method for the estimation of canagliflozin in bulk and pharmaceutical dosage forms. Int J Adv Pharm Ana 2017; 07(03):24-27.

53. Bhatt D, Thatavarthi RB. Analytical method development and validation for the estimation of canagliflozin in bulk and formulation by RP-HPLC. Int J Pharm Sci Drug Res 2018;10(3):139-43.

54. Sreenivasulua S, Raob MR, ChandraSekhar KB. A validated reverse phase liquid chromatographic method for the determination of canagliflozin, world J of Pharm Sci; 6(2) 1119-32.

55. Kaur I, Wakode S, Singh HP, Manachanda S. Development and validation of a stability-indicating reverse phase Hplc-Pda method for determination of canagliflozin in bulk and pharmaceutical dosage form. Pharmaceutical Methods 2016;7(1) 54-62.

56. Ladva BJ, Dobariya PV, Pancholi HD, Nayak BS, Jain S. Development and validation of chromatographic method for estimation of canagliflozin in API and tablet dosage form. Int J Recent Sci Res 2016;7(5):10976-79.

57. Bakshi A, Reddy NS, Bhutada S, Raju MB. Analytical method development and validation of canagliflozin and metformin Hcl by using Rp – Hplc. Int J Pharm Sci. 2018;12(4):122-30.

58. Gaware D, Patil RN, Harole M. A validated stability indicating Rp-Hplc method for simultanious determination of metformin and canagliflozin in pharmaceutical formulation. World J Pharm Sciences.2017;4(12):631-40.

59. Bangaruthalli J, Gowri DS, Renuka MN, Akhila P, Vanga D. Method development and validation of simultaneous estimation of metformin and canagliflozin by using Rp-Hplc. Int J Sci and Eng Res 2018;9(11)1309-19.

60. Kavuluru VS, Kothapallibonnath CS. Characterization and evaluation of empagliflozin spherical agglomerates by direct compression method. Int J Recent Sci Res 2018;9(2):24394-98.

61. https://patents.google.com/patent/WO2017114227A1/en.

62. Bhatta RG, Sadashivaiah R, Kotappa SBB. Formulation, optimization and evaluation of in-situ gelling liquid oral formulation of a novel antidiabetic drug: canagliflozin. Ind J Pharm Edu Res. 2019;53(2) 121-28.

63. Srinivas M, Gulle SB, Devilal J, Nanumala SK: Development and in vitro characterization of canagliflozin sustained release matrix tablets. 2016; vol. 6 (2): 258-280.